Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00394082 · ClinicalTrials.gov registry record · Phase 2
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00394082 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 50 participants.
The verdict
NCT00394082, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Interventions
- DRUG Bevacizumab
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-06-01 |
| Est. Completion | 2011-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00394082
The ClinicalTrials.gov registry entry for NCT00394082 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00394082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00394082 about?
NCT00394082 is a clinical study titled "ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer". The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
What is the current status of trial NCT00394082?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-06-01. Estimated completion is 2011-02-01.
What interventions are being tested in trial NCT00394082?
The interventions under investigation include: Bevacizumab (DRUG), ABI-007 (DRUG).
Who is sponsoring clinical trial NCT00394082?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.